Objective-Besides its well-described metabolic effects, vascular AMP-activated protein kinase (AMPK) can activate endothelial NO synthase, promotes angiogenesis, and limits endothelial cell apoptosis. The current study was designed to study the effects of ␣1AMPK deletion during vascular disease in vivo. Methods and Results-Chronic angiotensin II infusion at low subpressor doses caused a mild endothelial dysfunction that was significantly aggravated in ␣1AMPK-knockout mice. Unexpectedly, this endothelial dysfunction was not associated with decreased NO content, because NO levels measured by serum nitrite or electron paramagnetic resonance were even increased. However, because of parallel superoxide production, NO was consumed under production of peroxynitrite in angiotensin II-treated ␣1AMPK-knockout mice, associated with NADPH oxidase activation and Nox2 upregulation. As Nox2 is also a component of phagocyte NADPH oxidases, we found a vascular upregulation of several proinflammatory markers, including inducible NO synthase, vascular cell adhesion molecule-1, and cyclooxygenase-2. Cotreatment with the NADPH oxidase inhibitor apocynin was able to prevent vascular inflammation and also partially restored endothelial function in ␣1AMPK-knockout mice. Key Words: angiotensin II Ⅲ endothelium Ⅲ nitric oxide Ⅲ reactive oxygen species Ⅲ vascular biology A MP-activated protein kinase (AMPK) is a ubiquitous, heterotrimeric serine-threonine kinase that enables cells to cope with decreased ATP supply. Mainly, it switches off ATP consuming metabolic pathways (eg, cholesterol synthesis, fatty acid synthesis) while it promotes ATP-producing pathways, such as glycolysis and fatty acid oxidation. Given its multiple metabolic effects, AMPK plays a central role in the development and therapy of metabolic disorders, such as diabetes and obesity, and has been recognized as a possible drug target. 1 In the cardiovascular system, its ability to attenuate tissue damage during metabolic stress has important implications. For example, mice expressing a kinase-dead mutant of AMPK show aggravated myocardial injury after ischemia compared with wild-type (WT) mice. 2 Many of the metabolic effects of AMPK have been attributed to the ␣2-isoform, 3,4 but it is important to stress that vascular tissue almost exclusively expresses the ␣1-isoform containing AMPK. 5, 6 Emerging data suggest that AMPK has distinct physiological functions in the vascular system. For example, AMPK can induce endothelial NO production by activating endothelial nitric oxide synthase (eNOS) 7, 8 and acts as a signal to promote angiogenesis. 9 AMPK activation decreases angiotensin II (ATII)-induced smooth muscle proliferation 10 and diminishes endothelial cell apoptosis. 11 Because all these effects are of importance in the development of vascular disease and atherosclerosis, AMPK activation might be a supporting element in protecting vascular homeostasis. During vascular disease, activation of the renin-angiotensin system and increased oxidative stress are common and might bring about basal changes in activity or expression of AMPK. In fact, hydrogen peroxide and ATII are both known to
A MP-activated protein kinase (AMPK) is a ubiquitous, heterotrimeric serine-threonine kinase that enables cells to cope with decreased ATP supply. Mainly, it switches off ATP consuming metabolic pathways (eg, cholesterol synthesis, fatty acid synthesis) while it promotes ATP-producing pathways, such as glycolysis and fatty acid oxidation. Given its multiple metabolic effects, AMPK plays a central role in the development and therapy of metabolic disorders, such as diabetes and obesity, and has been recognized as a possible drug target. 1 In the cardiovascular system, its ability to attenuate tissue damage during metabolic stress has important implications. For example, mice expressing a kinase-dead mutant of AMPK show aggravated myocardial injury after ischemia compared with wild-type (WT) mice. 2 Many of the metabolic effects of AMPK have been attributed to the ␣2-isoform, 3, 4 but it is important to stress that vascular tissue almost exclusively expresses the ␣1-isoform containing AMPK. 5, 6 Emerging data suggest that AMPK has distinct physiological functions in the vascular system. For example, AMPK can induce endothelial NO production by activating endothelial nitric oxide synthase (eNOS) 7, 8 and acts as a signal to promote angiogenesis. 9 AMPK activation decreases angiotensin II (ATII)-induced smooth muscle proliferation 10 and diminishes endothelial cell apoptosis. 11 Because all these effects are of importance in the development of vascular disease and atherosclerosis, AMPK activation might be a supporting element in protecting vascular homeostasis. During vascular disease, activation of the renin-angiotensin system and increased oxidative stress are common and might bring about basal changes in activity or expression of AMPK. In fact, hydrogen peroxide and ATII are both known to activate AMPK in cultured cells, 12 and it is tempting to speculate that this activation might attenuate tissue damage from oxidative stress. However, most of the data on vascular AMPK function have been derived from experiments using tissue cultures, and the mechanism by which AMPK activity protects vascular tissue in vivo needs further investigation. Therefore, the current study was designed to investigate the vascular effects of AMPK deletion in vivo.
Materials and Methods
Male littermates of ␣1AMPK-knockout mice received ATII infusion for 7 days (0.1 mg/kg per day), and a subset of animals was treated with apocynin (30 mg/kg per day) in parallel to inhibit NADPH oxidase activity. AMPK activity was determined by Thr172 AMPK phosphorylation, and protein expression was assessed by SDS-PAGE followed by immunoblotting. Endothelial function was measured in organ chambers by isometric tension experiments using the vasodilation in response to acetylcholine. Vascular NO production was determined by electron paramagnetic resonance and plasma nitrite formation. Vascular oxidative stress and peroxynitrite formation were analyzed by dihydroethidium staining or nitrotyrosine staining of aortic sections and L-012 enhanced chemiluminescence. Aortic mRNA was assessed by realtime quantitative reverse transcription polymerase chain reaction (PCR). NADPH oxidase activity was determined in aortic membrane fractions using cytochrome c reduction.
For detailed protocols, please refer to the Supplemental Materials, available online at http://atvb.ahajournals.org.
Results

Effects of ␣1AMPK Deletion on Blood Pressure, Metabolism, Liver, and Kidney Function
In WT and ␣1AMPK-knockout mice, we observed no significant increase in blood pressure after 7 days of low-dose ATII treatment ( Figure 1A ). Body weight was assessed in all animal groups at the end of the treatment period and showed no significant differences (Supplemental Figure I) . To rule out effects on the vasculature secondary to changes in glucose or lipid metabolism in ␣1AMPK-knockout mice, we measured fasting glucose, triglyceride, and cholesterol levels in a subset of animals and found no significant change among all groups (Supplemental Figure IIA to IIC) . Similarly, liver and kidney function as measured by serum creatinine, blood urea nitrogen, glutamic oxaloacetic transaminase, and glutamic pyruvic transaminase was not altered after ␣1AMPK deletion or ATII treatment (Supplemental Table I ).
Aortic AMPK Activity Is Increased by Chronic Treatment With ATII In Vivo
Chronic ATII treatment resulted in a strong increase in vascular AMPK activity as monitored by AMPK phosphorylation at threonine 172 and phosphorylation of its downstream target acetyl-CoA carboxylase at serine 79 ( Figure  1B ). Although deletion of the ␣1AMPK isoform lead to a reduction of Ϸ80% in total AMPK expression, no compensatory upregulation of the ␣2AMPK isoform was observed ( Figure 1B) .
Effects of ␣1AMPK Deletion on Endothelial Dysfunction and Vascular NO Production
Although low-dose ATII treatment caused mild endothelial dysfunction in WT animals, ␣1AMPK-knockout mice displayed a significant further impairment of endothelial function ( Figure 2A) . Similarly, endothelial-independent relaxation was further impaired in ATII-treated ␣1AMPK-knockout mice ( Figure 2B ). Endothelial function largely depends on the critical balance between vascular NO production and its inactivation by reactive oxygen species (ROS), in particular superoxide anions. Because AMPK can stimulate vascular NO production in cultured endothelial cells, 7, 8 we next investigated whether impairment of endothelial function by deletion of ␣1AMPK is due to decreased NO production, increased vascular ROS production, or a combination of both. Surprisingly, ␣1AMPK-knockout mice showed no decrease in serum nitrite levels as an indicator of vascular NO production ( Figure 2C ). Nitrite levels were even increased in ␣1AMPK-knockout mice compared with WT mice, and this was true for ATII-treated mice, as well as for untreated control mice. To scrutinize this unexpected finding, we measured vascular NO production directly using electron paramagnetic resonance spectroscopy as described 13 and obtained a similar result, thus confirming that NO was indeed increased in ␣1AMPK-knockout mice as compared with WT mice ( Figure 2D and 2E). We found no significant change in total eNOS protein expression, whereas eNOS phosphorylation at serine 1177 was decreased to a similar extent in WT and ␣1AMPK-knockout mice during ATII treatment ( Figure 2F ). 
Effects of ␣1AMPK Deletion on Vascular Oxidative Stress and Peroxynitrite Formation
As the unexpected increase in NO levels after ␣1AMPK deletion could not account for the observed impairment of endothelial function in ATII-treated mice, one possible explanation would be that parallel production of superoxide anions leads to NO scavenging under formation of peroxynitrite. Indeed, by using the dot blot technique with a nitrotyrosine-specific antibody as a marker for peroxynitrite formation, we found highest levels in aortas from ␣1AMPK-knockout animals treated with ATII ( Figure 3A ). Immunostaining using a nitrotyrosine antibody revealed that peroxynitrite formation occurred in all animal groups in the adventitia, whereas only ␣1AMPK-knockout mice treated with ATII displayed a positive nitrotyrosine staining of the endothelium, compatible with increased endothelial peroxynitrite formation in this setting ( Figure 3B ). In addition, we observed a striking increase of the L-012 enhanced chemiluminescence signal in ATII-treated ␣1AMPK-knockout mice as a measure of increased peroxynitrite/ Figure 2 . Deletion of ␣1AMPK enhances endothelial dysfunction but increases vascular NO production during chronic ATII treatment. A and B, Endothelialdependent relaxation in response to acetylcholine (ACh) and endothelialindependent relaxation in response to nitroglycerin (NTG) were determined by isometric tension studies in intact aortic rings (3 mm in length) ex vivo. Data are meansϮSEM of nϭ10 independent experiments. Significance was tested using EC 50 values and maximum relaxation; *PϽ0.05 versus untreated WT; ‡PϽ0.05 versus ATII-treated WT mice (WTϩATII). Vascular NO production was determined by 2 independent assays. C, First, serum nitrite levels were determined using an NO analyzer. Data are meansϮSEM of nϭ6. D and E, Aortic NO production was also measured using electron paramagnetic resonance spectroscopy. Intensity (I) of the characteristic NO-Fe(diethyldithiocarbamate) 2 superoxide formation ( Figure 3C ). We assessed vascular superoxide production by dihydroethidium staining of aortic cryosections, which was not changed in untreated ␣1AMPK-knockout mice. Chronic ATII infusion increased superoxide levels in all layers of the vascular wall, with a further aggravation in ␣1AMPK-knockout animals ( Figure 3D ).
Taken together, these results indicate that ␣1AMPK deletion leads to increased NO and ROS production in parallel, resulting in NO scavenging by superoxide anions and subsequent peroxynitrite formation.
␣1AMPK Deletion Leads to Increased NADPH Oxidase Activity by Upregulation of Nox2
ATII is a potent stimulator of vascular ROS production driven by NADPH oxidase in cultured vascular smooth muscle cells 14 and in vascular tissue in vivo. 15 Low-dose ATII treatment did not increase vascular NADPH oxidase activity in WT animals, whereas deletion of the ␣1AMPK augmented NADPH oxidase driven superoxide production ( Figure 4A ). Although expression studies in our model of low-dose ATII treatment showed no significant change in vascular Nox1, Nox2, or p22phox expression in WT animals at the mRNA level, ␣1AMPK deletion led to a 5-fold increase in aortic Nox2 expression after ATII treatment ( Figure 4B ). This finding was confirmed at the protein level by Nox2 immunoblotting and Nox2 immunohistochemistry showing a marked increase in vascular Nox2 protein expression after ATII infusion in ␣1AMPK-knockout mice, but not in WT mice ( Figure 4C and 4D) .
AMPK Modulates Vascular Inflammation Induced by ATII In Vivo
Because Nox2 is an essential component of the phagocytic NADPH oxidase, the observed effects of AMPK deletion might relate to increased vascular inflammation. ATII induces cytokines such as tumor necrosis factor ␣ with a subsequent upregulation of inducible endothelial NO synthase (iNOS), cyclooxygenase-2 (COX-2), and vascular cell adhesion molecule 1 (VCAM-1) in mouse aorta. To test whether AMPK might modulate the inflammatory response elicited by ATII, we analyzed the expression of the above-mentioned proinflammatory signaling pathways. After in vivo ATII application, the mRNA expression of iNOS, COX-2, and VCAM-1 was not significantly changed in WT mice, whereas mice lacking the ␣1AMPK isoform displayed a marked upregulation ( Figure 5A to 5C), which is attributable to accelerated vascular inflammation in the latter animals. This result was confirmed by immunoblotting, showing a marked increase in iNOS, COX-2, and VCAM-1 protein expression in ATII-treated ␣1AMPK-knockout mice ( Figure 5D ).
NADPH Oxidase Inhibition Prevents Vascular Inflammation and Improves Endothelial Function in ATII-Treated ␣1AMPK-Knockout Mice
To assess whether Nox2 upregulation is responsible for the observed changes in vascular inflammation and endothelial dysfunction, part of the ␣1AMPK-knockout animals received in parallel the NADPH oxidase inhibitor apocynin in vivo. Apocynin cotreatment decreased vascular ROS production ( Figure 6B ) and also prevented vascular inflammation assessed by aortic expression of iNOS, COX-2, and VCAM-1 ( Figure 6C to 6E ). Most importantly, apocynin also resulted in a significant improvement of endothelial function, indicating that Nox2 upregulation due to the loss of vascular AMPK activity has profound functional implications ( Figure 6A) . Interestingly, the mild endothelial dysfunction observed in ATII-treated WT animals was not corrected by apocynin cotreatment (Figure 6A ), which is in accordance with Figure   Figure 4 
Discussion
In this study, we have demonstrated that AMPK is a critical regulator of vascular inflammation, superoxide production, and endothelial function in vivo. During chronic treatment with a low dose of ATII, AMPK activity protected the vasculature, because knockout of the ␣1AMPK isoform resulted in increased vascular superoxide production, inflammation, and impairment of endothelial function. Our data suggest that AMPK-besides its well-defined role in cellular adaptation to energetic stress-is fundamental in preserving endothelial function during ATII challenge and therefore seems to be a protective component in vascular homeostasis.
Numerous studies have demonstrated AMPK-driven NO production in cultured endothelial cells by eNOS phosphorylation at serine 1177 7 and serine 633 16 and facilitating its association with heat shock protein 90. 8 In ␣1AMPK-knockout mice, we did not observe endothelial dysfunction, a loss of NO bioavailability, or decreased eNOS phosphorylation at serine 1177 under basal conditions. This might be due to residual AMPK activity by ␣2AMPK, which might partially compensate for the loss of ␣1AMPK activity because it constitutes up to 20% of total AMPK expression in the vasculature. 6 Alternatively, phosphorylation of eNOS in the absence of ␣1AMPK could be mediated by other kinases, as it was recently found that activation of eNOS by thrombin and bradykinin was AMPK independent. 17, 18 However, in untreated as well as in ATII-treated mice, we detected an increase in NO production after deletion of the ␣1AMPK subunit, rather than a decrease. This unexpected finding was not paralleled by changes in eNOS expression or serine 1177 phosphorylation, but it can be explained by the observed increase in iNOS expression after ␣1AMPK deletion.
Increasing NOS activity might be an attractive mechanism to counteract a loss in NO bioavailability. However, in the setting of increased oxidative stress it is questionable whether increasing NO production would be desirable. Superoxide anions react rapidly with NO under formation of peroxynitrite, an extremely reactive metabolite that can further aggravate endothelial function eg, by tyrosine nitration of prosta- In vivo NADPH oxidase inhibition prevents vascular inflammation and improves endothelial function in ␣1AMPK-knockout mice. ␣1AMPKϪ/Ϫ mice were treated with low-dose ATII with or without the NADPH oxidase inhibitor apocynin for 7 days. A, Endothelial function was assessed by isometric tension studies ex vivo using intact aortic rings. B, Representative dihydroethidium staining of aortic cryosections. E indicates the endothelium; A, adventitia. Lamina autofluorescence is green. C to E, As a surrogate of vascular inflammation, the mRNA expression of iNOS (C), COX-2 (D), and VCAM-1 (E) was detected in aortic tissue by reversetranscription real-time PCR. Data are meanϮSEM of nϭ4 to 8 independent experiments. **PϽ0.05 versus untreated ␣1AMPKϪ/Ϫ; ‡PϽ0.05 versus ATIItreated WT mice; §PϽ0.05 versus ATIItreated ␣1AMPKϪ/Ϫ. cyclin synthase 19 or the initiation of eNOS uncoupling. 20 To preserve endothelial function in our model, the prevention of exacerbated oxidative stress by basal ␣1AMPK activity seems to be a better way, because it prevents the formation of peroxynitrite (monitored by tyrosine nitration) and thereby maintains NO bioavailability.
We observed a strong AMPK activation even after lowdose ATII treatment, which was markedly attenuated in ␣1AMPK-knockout animals. Residual activity could be explained by remaining AMPK activity from ␣2-containing AMPK, whereas it is important to note that no compensatory increase in ␣2AMPK was observed in ␣1AMPK-knockout mice. It is questionable whether our observations are related specifically to ␣1AMPK or are just a result of diminished total AMPK activity after knockout of the major vascular isoform ␣1AMPK. A recent study in ␣2AMPK-knockout mice showed an impairment of endothelial function in a murine model of hypercholesterolemia, 21 suggesting that AMPK activity per se is able to preserve endothelial function. One possible explanation for the lack of effects in ␣1AMPK knockouts under basal conditions could be that other mechanisms (including residual ␣2AMPK activity) might compensate for the loss of vascular ␣1AMPK activity, whereas diminished AMPK activity during ATII infusion may prove the remaining mechanisms insufficient to prevent vascular ROS effects and inflammation, thus resulting in endothelial dysfunction. In addition to endothelial dysfunction, ATIItreated ␣1AMPK-knockout mice also showed a significant impairment of endothelial-independent relaxation in response to nitroglycerin. Because nitroglycerin bioactivation by the mitochondrial aldehyde dehydrogenase (ALDH-2) is redoxsensitive, 22, 23 the observed rightward shift of the nitroglycerin dose-response curve in ATII-treated AMPK-knockout mice is likely due to increased oxidative stress in these animals. Importantly, a recent work by Doughan et al demonstrated that ATII in fact increases mitochondrial ROS formation via activation of the NADPH oxidase. 24 We have identified the NADPH oxidase as an AMPKsensitive ROS source in vivo. In contrast to previous studies that identified a Nox1-containing NADPH oxidase as the major ATII driven ROS source, we observed a significant increase in Nox2 mRNA and protein. Surprisingly, expression of Nox1 was not affected by ATII treatment in either WT or ␣1AMPK-knockout mice. This finding might be due to the design of our experiments, which used a low, subpressor dose of ATII (0.1 mg/kg per day). As a consequence, we did not observe changes in Nox1 expression that usually occur with higher ATII doses as used in hypertension studies. 15, 25 The lower dose of ATII used here might be sufficient to cause vascular inflammation but not vascular Nox1 upregulation. Our experiments indicate Nox2 as the predominant AMPKsensitive source of ROS in the vasculature, because knockout of ␣1AMPK resulted in a significant increase in both Nox2 mRNA and protein during ATII treatment. A recent study in ␣2AMPK-knockout mice revealed upregulation of several NADPH oxidase subunits in vascular tissue. 21 As Nox2 is known to be a major component of endothelial and phagocytic NADPH oxidases, our results might indicate increased vascular inflammation in ␣1AMPK-knockout mice, which was confirmed by a significant upregulation of the proinflammatory markers iNOS, VCAM, and COX-2. This result is in line with previous observations showing that basal ␣1/ ␣2AMPK activity in macrophages plays a fundamental role in the polarization to an antiinflammatory phenotype. 26 However, it remains an important question whether the observed Nox2 upregulation has implications for vascular inflammation and function or is just an innocent bystander. This issue was addressed by in vivo NADPH oxidase inhibition by apocynin treatment, which prevented vascular inflammation and also partially restored endothelial function. However, apocynin may act as an antioxidant, which could have contributed to the observed effects on oxidative stress and endothelial function. Taken together, our results show that the upregulation of Nox2 due to a loss of vascular AMPK activity can have fundamental functional implications for the vasculature. The exact mechanisms whereby AMPK regulates Nox2 expression remain unclear at the moment. ATII is a well-established stimulus for Nox2 upregulation in arteries, 15, 27 and AMPK may interfere with the involved ATIIdependent signaling processes. However, these signaling events may not interfere with the ATII pressor effects, because ␣1AMPK deletion did not affect blood pressure during low-dose ATII infusion. These blood pressure-independent effects of Nox2 upregulation are in accordance with previous data, which showed decreased vascular hypertrophy and oxidative stress in response to ATII in Nox2-deficient mice but no change in ATII-induced blood pressure elevation. 28 
